Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer

Completed · Phase 2

Conditions studied: Endometrial Cancer

In brief

RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using arzoxifene hydrochloride may fight the endometrial cancer by blocking the use of estrogen by the tumor cells PURPOSE: This phase II trial is studying how well arzoxifene hydrochloride works in treating women with recurrent, advanced, or metastatic endometrial cancer.

Key facts

Study ID

NCT00003669

Run by

Eli Lilly and Company

Starts

1998-11-01

Expected to finish

2001-04-01

Last updated by the study team

2012-06-07

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Huntington Memorial Hospital — Pasadena, California, United States
• Ellis Fischel Cancer Center - Columbia — Columbia, Missouri, United States
• Washington University Barnard Cancer Center — St Louis, Missouri, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Lineberger Comprehensive Cancer Center, UNC — Chapel Hill, North Carolina, United States
• Arthur G. James Cancer Hospital - Ohio State University — Columbus, Ohio, United States
• Grant/Riverside Methodist Hospitals — Columbus, Ohio, United States
• University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma, United States
• Abington Memorial Hospital — Abington, Pennsylvania, United States
• U.S. Oncology — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.